Michele Stansfield is the Co-founder and CEO of Cauldron, a global biomanufacturer unlocking price parity for mainstream bio-manufactured goods. Michele was the driving force behind Cauldron’s management acquisition of Agritechnology, a bioscience company based in regional Australia that developed the proprietary hyper-fermentation technology at Cauldron’s core. Having served as Agritechnology’s General Manager for over a decade, using microbes to produce vaccines, food, feed and fuel, Michele has industry-leading expertise in the scale-up and commercialization of continuous fermentation biomanufacturing. With a background in biomedical science and cellular and molecular biology, Michele started her career with Pfizer focused on a novel pharmaceutical therapy used in the pork industry. Michele holds a BSc (Honours) in Biomedical Science, Cellular and Molecular Biology from the University of Western Sydney.